nach oben

Inflammopharmacology

Erschienen in:

01.10.2012 | Research Article

Atorvastatin inhibits the inflammatory response caused by anti-M₃ peptide IgG in patients with primary Sjögren’s syndrome

verfasst von: Silvia Reina, Daniela Passafaro, Leonor Sterin-Borda, Enri Borda

Erschienen in: Inflammopharmacology | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Experimental and clinical investigations have revealed that statins can down-regulate acute and chronic inflammatory processes. Whether statins express anti-inflammatory activities in the salivary glands in patients with primary Sjögren’s syndrome (pSS) is not known. The in vitro and in vivo effect of atorvastatin on rat submandibular gland treated with anti-M₃ peptide IgG purified from SS patients was studied. The anti-inflammatory effects of atorvastatin were assessed by measuring the levels of IL-1β, PGE₂ and MMP-3 by ELISA. Atorvastatin inhibited the increase in the production of IL-1β, PGE₂ and MMP-3 in submandibular glands treated with anti-M₃ peptide IgG. A positive correlation between IL-1β production with accumulation of PGE₂ and MMP-3 was observed. Rats pre-treated orally with atorvastatin (30 mg kg⁻¹) or vehicle (phosphate-buffered solution) once a day for three consecutive days impaired the increment in the production of IL-1β, PGE₂ and MMP-3 in the submandibular gland in the presence of anti-M₃ peptide IgG. In conclusion, the anti-inflammatory effects of atorvastatin are dependent upon inhibition of production of a pro-inflammatory cytokine (IL-1β) and pro-inflammatory mediators such as PGE₂ and MMP-3. These data suggest that atorvastatin may constitute an anti-inflammatory effect in SS.

Bacman S, Perez Leiros C, Sterin-Borda L, Hubscher O, Arana R, Borda E (1998) Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sjögren’s syndrome. Invest Ophthalmol Vis Sci 39:151–156PubMed

Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V et al (2005) Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 516:282–289PubMedCrossRef

Baturone R, Soto MJ, Márquez M, Macías I, de Oca MM, Medina F, Chozas N, García-Pérez S, Girón-González JA (2009) Health-related quality of life in patients with primary Sjögren’s syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol 38:386–389PubMedCrossRef

Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J (2003) Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63:12–23PubMedCrossRef

Bolstad AI, Eiken HG, Rosenlund B, Alarcón-Riquelme ME, Jonsson R (2003) Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren’s syndrome. Arthritis Rheum 48:174–185PubMedCrossRef

Borda E, Sterin-Borda L (2001) Autoantibodies against neonatal heart M1 muscarinic acetylcholine receptor in children with congenital heart block. J Autoimmun 16:143–150PubMedCrossRef

Borda E, Passafaro D, Reina S, Sterin-Borda L (2011) Modulation of c-Jun NH₂-terminal (JNK) by cholinergic autoantibodies from patients with Sjögren’s syndrome. Pharmacol Pharm 2:256–265

Cao C, Matsumura K, Yamagata K, Watanabe Y (1996) Endothelial cells of the rat brain vasculature express cyclooxygenase-2 mRNA in response to systemic interleukin-1 beta: a possible site of prostaglandin synthesis responsible for fever. Brain Res 733:263–272PubMedCrossRef

Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R (1995) Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 76:21A–28APubMedCrossRef

Cunha TM, Verri WA Jr, Silva JS, Poole S, Cunha FQ, Ferreira SH (2005) A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci USA 102:1755–1760PubMedCrossRef

Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331PubMedCrossRef

Gans KR, Galbraith W, Roman RJ, Haber SB, Kerr JS, Schmidt WK, Smith C, Hewes WE, Ackerman NR (1990) Anti-inflammatory and safety profile of DuP 697, a novel orally effective prostaglandin synthesis inhibitor. J Pharmacol Exp Ther 254:180–187PubMed

Goin JC, Perez-Leiros C, Borda E, Sterin-Borda L (1997) Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: functional and pathological implications. FASEB J 10:77–83

Gottenberg JE, Busson M, Loiseau P et al (2003) In primary Sjögren’s syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 48:2240–2245PubMedCrossRef

Gottenberg JE, Cagnard N, Lucchesi C et al (2006) Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci USA 103:2770–2775PubMedCrossRef

Grundy SM (1988) HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319:24–33PubMedCrossRef

Heerey A, Barry M, Ryan M, Kelly A (2000) The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 169:176–179PubMedCrossRef

Jouzeau JY, Terlain B, Abid A, Nédélec E, Netter P (1997) Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53:563–582PubMedCrossRef

Koh KK (2000) Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648–657PubMedCrossRef

Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H et al (2003) A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170:1524–1530PubMed

Lowry JR, Thiessen R Jr (1950) Studies of the nutritive impairment of proteins heated with carbohydrates; in vitro digestion studies. Arch Biochem 25:148–156PubMed

Mandl T, Hammar O, Theander E, Wollmer P, Ohlsson B (2010) Autonomic nervous dysfunction development in patients with primary Sjogren’s syndrome: a follow-up study. Rheumatology (Oxford) 49:1101–1106CrossRef

Nakamura H, Kawakami A, Eguchi K (2006) Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjögren’s syndrome. Transat Res 148:281–288CrossRef

Ng KP, Isenberg DA (2008) Sjögren’s syndrome: diagnosis and therapeutic challenges in the elderly. Drugs Aging 25:19–33PubMedCrossRef

Ogawa N, Ping L, Zhenjun L, Takada Y, Sugai S (2002) Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjögren’s syndrome. Arthritis Rheum 46:2730–2741PubMedCrossRef

Pflugfelder SC (2004) Antiinflammatory therapy for dry eye. Am J Ophthalmol 137:337–342PubMedCrossRef

Rapraeger A, Jalkanen M, Bernfield MJ (1986) Cell surface proteoglycan associates with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells. Cell Biol 103:2683–2696CrossRef

Reina S, Sterin-Borda L, Orman B, Borda E (2004) Autoantibodies against cerebral muscarinic cholinoceptors in Sjögren syndrome: functional and pathological implications. J Neuroimmunol 150:107–115PubMedCrossRef

Reina S, Orman B, Anaya JM, Sterin-Borda L, Borda E (2007) Cholinoreceptor autoantibodies in Sjögren syndrome. J Dent Res 86:832–836PubMedCrossRef

Reina S, Sterin-Borda L, Passafaro D, Borda E (2010) Muscarinic cholinoceptor activation by pilocarpine triggers apoptosis in human skin fibroblast cells. J Cell Physiol 222:640–647PubMed

Reina S, Sterin-Borda L, Passafaro D, Borda E (2011a) Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren’s syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E₂ (PGE₂) from the submandibular glands. Arch Oral Biol 56:413–420PubMedCrossRef

Reina S, Sterin-Borda L, Passafaro D, Borda E (2011b) Anti-M(3) muscarinic cholinergic autoantibodies from patients with primary Sjögren’s syndrome trigger production of matrix metalloproteinase-3 (MMP-3) and prostaglandin E(2) (PGE(2)) from the submandibular glands. Arch Oral Biol 56:413–420PubMedCrossRef

Rosenberg GA (2002) Matrix metalloproteinases in neuroinflammation. Glia 39:279–291PubMedCrossRef

Rosenson RS (1999) Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1:225–232PubMedCrossRef

Sachs D, Cunha FQ, Ferreira SH (2004) Peripheral analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proc Natl Acad Sci USA 101:3680–3685PubMedCrossRef

Santodomingo-Garzón T, Cunha TM, Verri WA Jr et al (2006) Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol 149:14–22PubMedCrossRef

Solheim S, Seljeflot I, Arnesen H, Eritsland J, Eikvar L (2001) Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 157:411–415PubMedCrossRef

Steinfeld S, Cogan E, King LS, Agre P, Kiss R, Delporte C (2001) Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren’s syndrome patients. Lab Invest 81:143–148PubMedCrossRef

Sumida T, Tsuboi H, Iizuka M, Nakamura Y, Matsumoto I (2010) Functional role of M₃ muscarinic acetylcholine receptor (M3R) reactive T cells and anti-M3R autoantibodies in patients with Sjögren’s syndrome. Autoimmun Rev 9:615–617PubMedCrossRef

Tonussi CR, Ferreira SH (1994) Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol 251:173–179PubMedCrossRef

Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM (1993) Preliminary criteria for the classification of Sjögren’s syndrome. Results from a prospective concerted action supported by the European Community. Arthritis Rheum 36:340–347PubMedCrossRef

Waterman SA, Gordon TP, Rischmueller M (2000) Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren’s syndrome. Arthritis Rheum 43:1647–1654PubMedCrossRef

Weitz-Schmidt G (2002) Statins as anti-inflammatory agents. Trends Pharmacol Sci 23:482–486PubMedCrossRef

Titel: Atorvastatin inhibits the inflammatory response caused by anti-M3 peptide IgG in patients with primary Sjögren’s syndrome
verfasst von: Silvia Reina
Daniela Passafaro
Leonor Sterin-Borda
Enri Borda
Publikationsdatum: 01.10.2012
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammopharmacology / Ausgabe 5/2012
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-012-0132-x

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2012

Protective effect of aqueous extract of Spinacia oleracea leaves in experimental paradigms of inflammatory bowel disease

Effect of propolis on mast cells in wound healing

Some applications of pharmacogenomics and epigenetics in drug development and use in pursuit of personalized medicine

A review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics

Systemic alcohol-protective effects of quercetin besides its ameliorating effect on alcohol-induced neuropathic pain